Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice (Q43605712)

25 November 2017

Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice (English)

1 reference

25 November 2017

0 references

0 references

Ahrén B

1

1 reference

25 November 2017

1 February 2001

1 reference

25 November 2017

1 reference

25 November 2017

171

1 reference

25 November 2017

2

1 reference

25 November 2017

161-167

1 reference

Autonomic regulation of islet hormone secretion--implications for health and disease

25 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Role of glucose effectiveness in the determination of glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Stimulation of insulin secretion by infusion of free fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Metabolic origin of insulin resistance in obesity with and without type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Dysfunctional insulin secretion in type 2 diabetes: role of metabolic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Interaction between glucose and free fatty acid metabolism in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Lipid infusion lowers sympathetic nervous activity and leads to increased beta-cell responsiveness to glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Fatty acids, lipotoxicity and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Mechanisms modifying glucose oxidation in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Direct antidiabetic effect of leptin through triglyceride depletion of tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Diet-induced type II diabetes in C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

Strategies for the management of diabetic dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-201X.2001.00794.X

10.1046/J.1365-201X.2001.00794.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11350276